Cyclic bridged analogs of isoCA-4: Design, synthesis and biological evaluation.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
01 Jan 2021
Historique:
received: 21 08 2020
revised: 21 09 2020
accepted: 21 09 2020
pubmed: 11 10 2020
medline: 21 4 2021
entrez: 10 10 2020
Statut: ppublish

Résumé

In this work, a series of cyclic bridged analogs of isocombretastatin A-4 (isoCA-4) with phenyl or pyridine linkers were designed and synthesized. The synthesis of the desired analogs was performed by the formation of nitro-vinyl intermediates, followed by a Cadogan cyclization. Structure activity relationship (SAR) study demonstrates the critical role of the combination of quinaldine as ring A, pyridine as the linker, and indole as ring B in the same molecule, for the cytotoxic activity. Among all tested compounds, compound 42 showed the highest antiproliferative activity against a panel of cancer cell lines with average IC50 values of 5.6 nM. Also, compound 42 showed high antiproliferative activity against the MDR1-overexpressing K562R cell line; thus, it was 1.5- and 12-fold more active than the reference compounds, isoCA-4 and CA-4, respectively. Moreover, 42 displayed a strong antiproliferative activity against the colon-carcinoma cells (HT-29), which are resistant to combretastatin A-4 and isoCA-4, and it was found to be 8000-fold more active than natural CA-4. Compound 42 also effectively inhibited tubulin polymerization both in vitro and in cells, and induced cell cycle arrest in G2/M phase. Next, we demonstrated that compound 42 dose-dependently caused caspase-induced apoptosis of K562 cells through mitochondrial dysfunction. Finally, we evaluated the effect of compound 42 in human no cancer cells compared to the reference compound. We demonstrated that 42 was 73 times less cytotoxic than isoCA-4 in quiescent peripheral blood lymphocytes (PBLs). In summary, these results suggest that compound 42 represents a promising tubulin inhibitor worthy of further investigation.

Identifiants

pubmed: 33038796
pii: S0223-5234(20)30845-X
doi: 10.1016/j.ejmech.2020.112873
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Stilbenes 0
Tubulin 0
Tubulin Modulators 0
fosbretabulin I5590ES2QZ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112873

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Shannon Pecnard (S)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.

Olivier Provot (O)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.

Hélène Levaique (H)

Institut de Chimie des Substances Naturelles, UPR 2301, CNRS, F-91198, Gif sur Yvette, France.

Jérome Bignon (J)

Institut de Chimie des Substances Naturelles, UPR 2301, CNRS, F-91198, Gif sur Yvette, France.

Laurie Askenatzis (L)

Institut de Chimie des Substances Naturelles, UPR 2301, CNRS, F-91198, Gif sur Yvette, France.

Francois Saller (F)

INSERM, UMR-S1176, University Paris-Saclay, F-94276, Le Kremlin-Bicetre, France.

Delphine Borgel (D)

INSERM, UMR-S1176, University Paris-Saclay, F-94276, Le Kremlin-Bicetre, France.

Sophie Michallet (S)

Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, Grenoble, France.

Marie-Catherine Laisne (MC)

Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, Grenoble, France.

Laurence Lafanechère (L)

Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, Grenoble, France.

Mouad Alami (M)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.

Abdallah Hamze (A)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France. Electronic address: abdallah.hamze@universite-paris-saclay.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH